79T Stock Overview
Develops, manufactures, and markets e-health solutions in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Medimi AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0012 |
| 52 Week High | SEK 0.014 |
| 52 Week Low | SEK 0.0002 |
| Beta | -0.30 |
| 11 Month Change | 100.00% |
| 3 Month Change | 100.00% |
| 1 Year Change | -50.00% |
| 33 Year Change | -96.43% |
| 5 Year Change | n/a |
| Change since IPO | -97.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 79T | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | -0.1% |
| 1Y | -50.0% | 0.9% | 2.4% |
Return vs Industry: 79T underperformed the German Medical Equipment industry which returned 0.9% over the past year.
Return vs Market: 79T underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| 79T volatility | |
|---|---|
| 79T Average Weekly Movement | 80.8% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 79T's share price has been volatile over the past 3 months.
Volatility Over Time: 79T's weekly volatility has increased from 54% to 81% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 6 | Johan Wiesel | www.medimiab.com |
Medimi AB (publ) develops, manufactures, and markets e-health solutions in Sweden. It offers Medimi Smart, a comprehensive system for medicine handling; and MedimiFlex, an administration system. The company was formerly known as MedicPen AB (publ) and changed its name to Medimi AB (publ) in May 2021.
Medimi AB (publ) Fundamentals Summary
| 79T fundamental statistics | |
|---|---|
| Market cap | €2.45m |
| Earnings (TTM) | -€1.22m |
| Revenue (TTM) | €342.51k |
7.4x
P/S Ratio-2.1x
P/E RatioIs 79T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 79T income statement (TTM) | |
|---|---|
| Revenue | SEK 3.89m |
| Cost of Revenue | SEK 1.88m |
| Gross Profit | SEK 2.02m |
| Other Expenses | SEK 15.87m |
| Earnings | -SEK 13.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 51.77% |
| Net Profit Margin | -355.72% |
| Debt/Equity Ratio | 27.9% |
How did 79T perform over the long term?
See historical performance and comparison